Antitussive Pure Dextromethorphan Hydrobromide DXM Powder Pharmaceutical Grade CAS 6700-34-1

                       Antitussive Dextromethorphan Hydrobromide (DXM) Raw Powder
 
 
Description:
 
DXM is an antitussive (cough suppressant) drug. It is one of the active ingredients in many over-
 
the-counter cold and cough medicines, including generic labels and store brands, Benylin DM,
 
Mucinex DM, Robitussin, NyQuil, Dimetapp, Vicks, Coricidin, Delsym, TheraFlu, and others.
 
Dextromethorphan has also found other uses in medicine, ranging from pain relief to
 
psychological applications. It is sold in syrup, tablet, spray, and lozenge forms.
 
In its pure form, dextromethorphan occurs as a white powder.
 
 
Application:
 
DXM is also used recreationally. When exceeding label-specified maximum dosages,
 
dextromethorphan acts as a dissociative hallucinogen. Its mechanism of action is via multiple
 
effects, including actions as a nonselective serotonin reuptake inhibitor and a sigma-1 receptor
 
agonist. The major metabolite of DXM, dextrorphan, also acts as an NMDA receptor antagonist.
 
In high doses this produces effects similar to, yet distinct from, the dissociative states created by
 
other dissociative anaesthetic .
 
 
Usage:
 
1. An antitussive drug. Orally active synthetic morphine analog. Analgesic (narcotic).
 
Racemethorphan and levomethorpham are controlled substances (opiates).
 
2. Antitussive; Opioid ligand
 
 
Medical use:
 
Generic Dextromethorphan syrup.
 
The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of
 
cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu
 
and common cold), as well as those resulting from inhaled particle irritants.
 
A study showed that dextromethorphan was no more effective for children than a placebo.
 
Studies conducted by the American Academy of Pediatrics show that dextromethorphan is not
 
superior to a placebo in providing nocturnal symptom relief for children with cough and sleep
 
difficulty due to upper respiratory infections.
 
A combination of dextromethorphan and quinidine, a CYP2D6 inhibitor, has been shown to
 
alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with
 
amyotrophic lateral sclerosis and multiple sclerosis.Dextromethorphan is also being investigated
 
as a possible treatment for neuropathic pain and pain associated with fibromyalgia. In 2010, the
 
FDA approved the combination product dextromethorphan/quinidine (Nuedexta) for the treatment
 
of pseudobulbar affect (PBA).
 
 

 
 
Our advantages:
1. Quality products with factory price
 
2. We are manufacturer, products plenty in stock and orders can be delivered very quickly
 
3. Rich experienced shipping team, more than 98% success rate of delivery
 
4. Kind of shipping method : EMS, HKEMS, Fedex, TNT, UPS, DHL , Aramex
 
5. We have reship policy if you can't receive the parcels
 
6. 24/7 online after-sales service